Drug Trial Radar · NCT06495229
Study of CM310 in Adolescent Subjects With Atopic Dermatis
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 2, 2024
Primary completion
Aug 30, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
CM310Biological
Interleukin-4 receptor(IL-4Rα) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: up to week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.